Santen EMEA’s significant expansion into the surgical devices arena is underlined by the company’s activities at this year’s European Society of Cataract and Refractive Surgeons (ESCRS) congress. In addition to the launch of a new monofocal, hydrophobic intraocular lens (IOL), xact™ Mono-EDoF™, a panel of experts including Ike K. Ahmed, will review current surgical techniques and introduce Santen's PRESERFLO™ MicroShunt device. PRESERFLO™ MicroShunt is a state-of-the-art surgical device, designed in collaboration with ophthalmologists that helps to drain eye fluid and reduce intraocular pressure (IOP) for patients suffering from primary open-angle glaucoma (POAG). PRESERFLO™ is the new trademark of Innfocus MicroShunt®. PRESERFLO™ MicroShunt will replace Innfocus MicroShunt® in the future.
The 24-week results of PERSPECTIVE, an ongoing 12 month, non-interventional, multi-centre, European, prospective study have been presented at ESCRS 2019 as a poster. The study evaluated the effectiveness, tolerability and safety of cyclosporine A (CsA) 0.1% eye drop emulsion, marketed as IKERVIS®, in controlling severe keratitis and other parameters including improvement of symptoms, in adult dry eye patients, who had previously failed to respond to artificial tear treatments. The interim analysis data demonstrated that CsA 0.1% eye drop emulsion provides an effective, well tolerated and safe treatment at Week 24, compared with baseline, in adults with dry eye disease (DED) and severe keratitis. Key findings include:1
- CsA 0.1% eye drop emulsion provided significant improvements in corneal fluorescein staining (CFS) grade at Week 24 (77.4%)
- Statistically significant improvements were also demonstrated at Week 24, from baseline, concerning tear break-up time (TBUT) as well as objective and subjective measures
- Most physicians regarded CsA 0.1% eye drop emulsion to be more effective than previous treatments. Both physicians and patients rated the tolerability of treatment highly
- Most treatment-related adverse events (TRAEs) were localised at the administration site and 67.7% were recovered without issue
1. ESCRS PERSPECTIVE ePoster